Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have been assigned an average rating of “Moderate Buy” from the eighteen ratings firms that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and three have given a strong buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $110.5455.

A number of analysts have commented on GPCR shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Canaccord Genuity Group assumed coverage on Structure Therapeutics in a report on Monday, April 27th. They issued a “buy” rating and a $101.00 target price for the company. Finally, HC Wainwright reduced their price target on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, June 11th.

Institutional Trading of Structure Therapeutics

Institutional investors have recently made changes to their positions in the company. Orbimed Advisors LLC raised its position in Structure Therapeutics by 27.0% in the first quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company’s stock valued at $71,114,000 after purchasing an additional 313,600 shares during the period. Principal Financial Group Inc. boosted its position in Structure Therapeutics by 63.1% in the 4th quarter. Principal Financial Group Inc. now owns 1,284,210 shares of the company’s stock valued at $89,317,000 after buying an additional 496,726 shares during the period. SEB Asset Management AB purchased a new stake in shares of Structure Therapeutics during the first quarter worth $11,811,000. Peregrine Capital Management LLC acquired a new position in Structure Therapeutics during the 4th quarter worth $5,865,000. Finally, Siren L.L.C. raised its position in Structure Therapeutics by 23.2% in the 1st quarter. Siren L.L.C. now owns 1,328,698 shares of the company’s stock valued at $64,043,000 after purchasing an additional 250,000 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Performance

Shares of GPCR stock opened at $52.62 on Friday. Structure Therapeutics has a fifty-two week low of $15.85 and a fifty-two week high of $94.90. The stock’s fifty day moving average is $47.36 and its two-hundred day moving average is $54.20. The firm has a market capitalization of $3.74 billion, a P/E ratio of -60.48 and a beta of -1.43.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, equities analysts forecast that Structure Therapeutics will post -1.64 earnings per share for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.